English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Marta Barrachina1,2, Mairena Martin3, Francisco Ciruela4 and Isidre Ferrer1,2,5 1Institute of Neuropathology, Bellvitge University Hospital-ICS, (Bellvitge Biomedical Research Institute-) IDIBELL, L’Hospitalet de Llobregat, 2Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, CIBERNED, Barcelona, 3Departamento de Quimica Inorganica, Organica y Bioquimica, Facultad de Quimicas, Centro Regional de Investigaciones Biomedicas, Universidad de Castilla-La Mancha, Ciudad Real, 4University of Barcelona, Unit of Pharmacology, Department of Pathology and Experimental Therapeutics, L’Hospitalet de Llobregat, 5University of Barcelona, Department of Pathology and Experimental Therapeutics, L’Hospitalet de Llobregat, Spain

Epigenetic Modulation of Adenosine A2A Receptor: A Putative Therapeutical Tool for the Treatment of Parkinson’s Disease